This first-in-human, multi-centre, open-label, Phase 1 dose-escalation study (CITRINO, NCT03250832) of encelimab, a novel LAG-3 inhibitor, evaluated encelimab alone and in combination with dostarlimab in patients with previously treated advanced or metastatic solid tumours, including cohort expansion evaluating the combination with or without bevacizumab and mFOLFOX6 or FOLFIRI in PD-(L)1-naïve advanced or metastatic MSS CRC. The gene discussed is LAG3; the disease is colorectal carcinoma.